Abstract | BACKGROUND: The 5-HT(1B/1D) receptor agonist sumatriptan is highly effective in the treatment of migraine. However, some patients do not respond to sumatriptan or experience recurrence of the headache after initial relief. In addition, some patients report chest symptoms after the use of sumatriptan. OBJECTIVE: METHOD: Genomic DNA of a relatively small but very well-characterized set of migraine patients with consistently good response to sumatriptan (n = 14), with no response (n = 12), with recurrence of the headache (n = 12), with chest symptoms (n = 13), and patients without chest symptoms (n = 27) was available for the genetic analyses and screened for the F124C variant and the A-161T polymorphism in the human 5-HT(1B) receptor gene. RESULTS: F124C was not detected in any of the patients studied. In addition, we did not observe drastic changes in allele frequencies of the A-161T polymorphism that might hint to a causal relation with the therapeutic effect of sumatriptan. CONCLUSION: We have not obtained any evidence that variants F124C and A-161T of the 5-HT(1B) receptor are major determinants in the clinical response to sumatriptan.
|
Authors | Suneet Mehrotra, Kaate R J Vanmolkot, Rune R Frants, Arn M J M van den Maagdenberg, Michel D Ferrari, Antoinette MaassenVanDenBrink |
Journal | Headache
(Headache)
Vol. 47
Issue 5
Pg. 711-6
(May 2007)
ISSN: 0017-8748 [Print] United States |
PMID | 17501853
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Receptor, Serotonin, 5-HT1B
- Serotonin Receptor Agonists
- Phenylalanine
- Sumatriptan
- Cysteine
|
Topics |
- Adult
- Aged
- Cysteine
(genetics)
- DNA Mutational Analysis
- Female
- Gene Frequency
- Genetic Variation
- Humans
- Male
- Middle Aged
- Migraine Disorders
(drug therapy, genetics)
- Pharmacogenetics
- Phenylalanine
(genetics)
- Receptor, Serotonin, 5-HT1B
(genetics)
- Serotonin Receptor Agonists
(therapeutic use)
- Sumatriptan
(therapeutic use)
- Treatment Outcome
|